Karuna Therapeutics, Inc., A Bristol Myers Squibb Company

This study tested the long-term safety of KarXT, a new medication for schizophrenia, in 566 adults aged 18 to 65. Participants took KarXT twice daily for up to 52 weeks. The main goal was to see how safe and tolerable the drug is over time, with a focus on side effects. This is a…

This study tested whether adding KarXT (a combination of two medicines) to standard antipsychotic treatment helps reduce schizophrenia symptoms that were not well controlled. About 400 adults with schizophrenia took either KarXT or a placebo for 6 weeks. The main goal was to see …

This study tested a new drug called KarXT in 202 Chinese adults hospitalized with schizophrenia. For 5 weeks, some received KarXT and others a placebo to see if the drug reduces symptoms like hallucinations and social withdrawal. After that, everyone could take KarXT for 12 more …

This study looked at how a new drug called KarXT interacts with three common mood stabilizers (lithium, valproic acid, and lamotrigine) in 133 healthy volunteers. Researchers measured drug levels in the blood to see if combining them changes how each drug works. The goal is to en…